Google News: Geron Corp.
- Osiris Wins Canadian Approval for First Stem-Cell Therapy - Bloomberg
17 May 2012
- InVivo Therapeutics Chief Science Officer Edward Wirth to Discuss Biopolymers ... - MarketWatch (press release)
16 May 2012
- Increased Investment in Stem Cell Technologies Drives Stem Cell Research Market - BiotechStockTrader.com
11 May 2012
- Small Biotechs Like Aastrom Biosciences and Geron Likely to Benefit From New ... - MarketWatch (press release)
9 May 2012
- Zacks Gives Neutral Rating to Geron (GERN) - Junction Report
4 May 2012
|
Zacks Gives Neutral Rating to Geron (GERN) Junction Report In November 2011, Geron delivered a huge surprise by announcing its intention to exit the stem cell research market. The company, which was a leader in stem cell research, intends to focus on its oncology programs instead. While the decision to focus ...
|
- Geron Completes Enrollment in Phase 2 Clinical Trial of Imetelstat in Non ... - Reuters
3 May 2012
- U.S. Companies Reporting Higher Quarterly EPS, May 2 - Bloomberg
3 May 2012
|
U.S. Companies Reporting Higher Quarterly EPS, May 2 Bloomberg TICKER EST SYM COMPANY Q12 Q11 % CHG Q12 % CHG Q/E ======================================================================== VICL VICAL INC 0.00 -0.12 NM -0.08 NM Mar REXX REX ENERGY CORP 0.11 0.02 450.0 0.07 57.1 Mar NMRX NUMEREX CORP-A 0.10 0.02 400.0 ...
und weitere » |
- Geron Corporation Reports 2012 First Quarter Financial Results and Highlights - Reuters
2 May 2012
- DIARY - US Company Conference Call/Webcast for Day Ahead - Reuters
2 May 2012
- Geron Announces Conference Call to Discuss First Quarter 2012 Financial Results - MarketWatch (press release)
25 Apr 2012
|
Geron Announces Conference Call to Discuss First Quarter 2012 Financial Results MarketWatch (press release) Menlo Park, USA, Apr 25, 2012 (Thomson Reuters ONE via COMTEX) -- Menlo Park, Calif., April 25, 2012 - Geron Corporation (NASDAQ:GERN) will announce its financial results for the first quarter ended March 31, 2012 on Wednesday, May 2, 2012, ...
und weitere » |
|